BIIB

Oct 20, 11:03 AMBroad biotech-sector rally lifts Biogen 3.7% as Lilly, Amgen and Regeneron advance

Peers: NVS LLY SNY AMGN IONS GILD ARGX REGN SRPT SUPN

| Held by: VTI VOO VO IVV SPY VTV IBB XLV RSP VOE

Index	S&P 500
Market Cap	37.51B
Enterprise Value	44.58B
Income	834.60M
Sales	9.66B
Book/sh	127.61
Cash/sh	8.70
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	7500
IPO	Sep 17, 1991

P/E	44.95
Forward P/E	15.47
PEG	2.30
P/S	3.88
P/B	1.99
P/C	29.19
P/FCF	13.91
EV/EBITDA	16.35
EV/Sales	4.61
Quick Ratio	1.26
Current Ratio	1.87
Debt/Eq	0.44
LT Debt/Eq	0.40
Option/Short	Yes / Yes

EPS (ttm)	5.65
EPS next Y	16.41
EPS next Q	1.97
EPS this Y	-19.22%
EPS next Y	32.93%
EPS next 5Y	6.74%
EPS past 3/5Y	-25.04% -18.74%
Sales past 3/5Y	0.35% -5.06%
EPS Y/Y TTM	-45.79%
Sales Y/Y TTM	0.53%
EPS Q/Q	-84.85%
Sales Q/Q	2.38%
Earnings	Oct 28 BMO
EPS/Sales Surpr.	22.49% 11.20%

Insider Own	0.75%
Insider Trans	-0.11%
Inst Own	98.71%
Inst Trans	3.13%
ROA	2.76%
ROE	4.58%
ROIC	3.16%
Gross Margin	64.29%
Oper. Margin	19.50%
Profit Margin	8.64%
SMA20	9.85%
SMA50	13.60%
SMA200	27.26%
Trades

Shs Outstand	147.70M
Shs Float	146.64M
Short Float	4.07%
Short Ratio	5.80
Short Interest	5.97M
52W High	254.41 -0.22%
52W Low	138.00 83.94%
Volatility	3.02% 2.73%
ATR (14)	6.58
RSI (14)	75.14
Beta	0.12
Rel Volume	0.01
Avg Volume	1.03M
Volume	462

Perf Week	9.11%
Perf Month	12.14%
Perf Quarter	26.83%
Perf Half Y	37.67%
Perf YTD	44.24%
Perf Year	69.14%
Perf 3Y	0.18%
Perf 5Y	-4.14%
Perf 10Y	-5.18%
Recom	1.84
Target Price	247.55
Prev Close	253.84
Price	253.84
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-12-26	Upgrade	JP Morgan	Neutral → Overweight	$300
Aug-13-26	Upgrade	Wolfe Research	Peer Perform → Outperform	$300
Jul-13-26	Upgrade	Truist	Hold → Buy	$235
Jun-08-26	Upgrade	Needham	Hold → Buy	$255
May-15-26	Resumed	Evercore ISI	Outperform
Apr-22-26	Upgrade	UBS	Neutral → Buy	$225
Apr-20-26	Upgrade	Wells Fargo	Equal Weight → Overweight	$250
Apr-14-26	Upgrade	Piper Sandler	Neutral → Overweight	$214
Feb-20-26	Initiated	Barclays	Equal Weight	$185
Feb-09-26	Reiterated	H.C. Wainwright	Buy	$194 → $228
Jan-07-26	Resumed	UBS	Neutral	$185
Dec-10-25	Downgrade	HSBC Securities	Hold → Reduce	$143
Nov-06-25	Upgrade	Stifel	Hold → Buy	$202
Sep-25-25	Initiated	Jefferies	Buy	$190
Jul-21-25	Resumed	Truist	Hold	$142
Apr-28-25	Downgrade	HSBC Securities	Buy → Hold	$118
Apr-04-25	Downgrade	Argus	Buy → Hold
Feb-11-25	Initiated	Bernstein	Mkt Perform	$160
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164

Show Previous Ratings

Oct-22-26 01:08PM	The Week Ahead: Wall Street Awaits October Fed Decision (Schaeffer's Research) +5.34%
08:00AM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates (Business Wire)
Oct-20-26 03:27PM	RBC Capital names top healthcare stocks as sector upgraded to overweight (Investing.com)
Oct-19-26 07:30AM	Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week (GlobeNewswire)
Oct-16-26 01:46PM	Another Biotech IPO Pops on Rough Day for Broader Market (Barrons.com)
06:30AM	Loading…
06:30AM	Biogen-backed Estuary nabs $93M for kidney disease gene therapy (BioPharma Dive)
Oct-12-26 12:37PM	Biogen Stock Could Keep Gaining. A J.P. Morgan Upgrade Is Just the Beginning. (Barrons.com)
09:49AM	3 Big Names Enjoying Renewed Analyst Backing (Schaeffer's Research)
09:41AM	Salesforce upgraded, Adobe downgraded: Wall Street's top analyst calls (The Fly)
07:51AM	JPMorgan gets bullish on Biogen ahead of 2027 catalysts (Investing.com)
07:33AM	BIIB Stock: JPMorgan Sees Increasingly Compelling Catalyst Path For Biogen, Raises Price Target To $300 (Stocktwits)
Oct-06-26 01:06PM	Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says (Proactive)
Oct-02-26 11:20AM	Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus (GlobeNewswire)
Sep-29-26 12:23AM	Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? (Stocktwits)
Sep-23-26 04:01PM	Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization (Business Wire)
08:41AM	Loading…
08:41AM	Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets (TIKR)
Sep-21-26 11:55AM	Novo Nordisk shares plunge over 7% as new targets fail to reassure investors (Proactive)
Sep-17-26 04:15PM	Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN (GlobeNewswire)
Sep-16-26 02:00AM	LEQEMBI Pen (Subcutaneous Formulation of LEQEMBI) Approved in Japan for the Treatment of Early Alzheimer's Disease (GlobeNewswire)
Sep-04-26 12:13PM	This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging. (Barrons.com)
Sep-03-26 07:30PM	Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) (GlobeNewswire)
12:00AM	LEQEMBI (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China (GlobeNewswire)
Sep-02-26 08:00AM	Stoke Therapeutics to Present at the Cantor Global Healthcare Conference (Business Wire)
Sep-01-26 10:00AM	Stoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congress (InvestorsHub)
07:30AM	Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) (GlobeNewswire)
Aug-31-26 07:30PM	Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI (lecanemab) for Early Alzheimer's Disease (GlobeNewswire)
Aug-27-26 01:01AM	Veeva Systems Inc (VEEV) (Q2 2027) Earnings Call Highlights: Record CRM Quarter and AI Momentum ... (GuruFocus.com)
Aug-24-26 08:04AM	LEQEMBI IQLIK (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease (GlobeNewswire)
Aug-19-26 12:32PM	Real Parkinsons Disease Hope from Jupiter Neurosciences (Exec Edge)
Aug-13-26 09:52AM	Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation (Investing.com)
06:15PM	Loading…
Aug-06-26 06:15PM	Biogen Completes Acquisition of RayThera Inc. (GlobeNewswire)
Aug-05-26 08:00AM	Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference (Business Wire)
Aug-03-26 04:01PM	Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
Jul-31-26 03:29PM	Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap? (Trefis)
Jul-29-26 05:03PM	Biogen Inc (BIIB) Q2 2026 Earnings Call Highlights: Strong Growth in Core Pharmaceuticals and ... (GuruFocus.com)
01:22PM	Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views (Investor's Business Daily)
08:16AM	Biogen Beats Second-Quarter Expectations as Growth Portfolio Drives Revenue Higher (InvestorsHub)
07:13AM	Earnings roundup: Biogens resiliency, AstraZenecas growth pitch and GSKs oncology push (BioPharma Dive)
06:45AM	Biogen Q2 revenue, adjusted EPS beat estimates as growth portfolio lifts sales (Investing.com)
06:23AM	Biogen Cuts FY Adjusted View as Profit Declines (The Wall Street Journal)
06:02AM	Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs (Barrons.com)
Jul-27-26 04:01PM	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates (Business Wire)
Jul-20-26 12:15PM	VERAXA Biotech Shows Regulatory Progress on Cancer Therapy Platform (Exec Edge)
Jul-16-26 12:18PM	Slate Medicines Appoints Mark W. Hahn to Board of Directors (Exec Edge) +5.92%
07:47AM	Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide (PR Newswire)
Jul-15-26 11:23AM	Acumen Pharmaceuticals Shows Early Alzheimers Disease Insights (Exec Edge)
08:15AM	Biogen Appoints Michael J. Parini as Chief Legal Officer (GlobeNewswire)
07:25AM	AAIC26: Biogen stock drops after unveiling tau-targeting ASO data (Clinical Trials Arena)
Jul-14-26 02:38PM	BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimers Drug Benefits Will Replicate In Further Study (Stocktwits) -8.17%
02:09PM	Biogen's Alzheimer's Drug Leaves Questions Unanswered, and That's a Problem (Barrons.com)
01:40PM	Biogen stock sinks after Alzheimer's drug trial data fails to impress investors (Quartz)
01:36PM	Biogen stock falls 8% on Alzheimer's drug diranersen trial data (Quartz)
12:12PM	Biogen Stock Sinks on Lackluster Alzheimer's Results (The Wall Street Journal)
12:01PM	Biogen tumbles 8.7% as breakthrough Alzheimers data is clouded by dosing paradox (Investing.com)
11:18AM	LEQEMBI Real-World LEADER Study Presented at AAIC 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment (GlobeNewswire)
09:48AM	Biogen Shares Rise After Positive Phase 2 Alzheimer's Trial Results (BIIB) (InvestorsHub)
09:19AM	Can Biogen Score Another Win In Alzheimer's Disease? (Investor's Business Daily)
09:15AM	Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease (GlobeNewswire)
Jul-13-26 05:38PM	FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease (GlobeNewswire)
04:30PM	Biogen Inc. stock outperforms competitors on strong trading day (MarketWatch)
03:21PM	BIIB Stock Jumps 5% Analysts Raise Price Targets After FDA Clears Alzheimers Treatment For At-Home Use (Stocktwits)
09:41AM	American Express, Biogen upgraded: Wall Street's top analyst calls (The Fly)
08:31AM	Truist upgrades Biogen to Buy on Alzheimers, pipeline optimism ahead of key data (Investing.com)
08:15AM	Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer's Drug Study Details (Barrons.com)
07:30AM	Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer (Business Wire)
02:00AM	Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's? (Barrons.com)
Jul-12-26 11:18AM	LEQEMBI Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference (AAIC) 2026 (GlobeNewswire)
Jul-10-26 07:35AM	The Long Climb Back For Ionis Stock (Trefis)
Jul-07-26 05:39AM	Vertex to acquire Crinetics in $10B foray into endocrine disease drugs (BioPharma Dive)
Jul-06-26 02:04PM	3 Healthcare ETFs to Own in a Choppy Stock Market (Barrons.com)
Jul-02-26 07:53PM	BIIB Stock Ends 3% Higher Why This Strategist Picks Biogen Over Other Biotech Peers (Stocktwits)
Jun-29-26 07:42AM	Biogen trims Apellis pipeline and R&D team after $5.6bn takeover (Pharmaceutical Technology)
06:59AM	Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen (GlobeNewswire)
Jun-26-26 04:30PM	Biogen Inc. stock outperforms competitors on strong trading day (MarketWatch) +6.97%
01:49PM	Lilly, J&J and AbbVie Hit New Highs (GuruFocus.com)
Jun-19-26 05:48AM	Biogen to acquire RayThera for up to $1bn (Pharmaceutical Technology)
Jun-18-26 09:40AM	Biogen acquires RayThera in deal worth up to $1 billion (Quartz)
07:12AM	Biogen adds more immune drugs in $1B buyout of secretive startup RayThera (BioPharma Dive)
Jun-17-26 08:03PM	BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal (Stocktwits)
06:59PM	Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc. (GlobeNewswire)
Jun-16-26 06:18PM	Acumen Nominates 2 Therapies to Treat Alzheimers Disease (Exec Edge)
Jun-05-26 06:05AM	Biogen's salanersen gains FDA breakthrough therapy designation for SMA (Pharmaceutical Business Review)
Jun-04-26 07:30AM	Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy (GlobeNewswire)
01:00AM	EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus (GlobeNewswire)
Jun-03-26 07:30AM	Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses (GlobeNewswire)
03:30AM	Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick. (Barrons.com)
03:15AM	Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors (TMX Newsfile)
Jun-01-26 01:30AM	UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus (GlobeNewswire)
May-28-26 04:01PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in June (Business Wire)
May-22-26 06:46AM	Parkinsons drug from Biogen, Denali comes up short (BioPharma Dive)
May-21-26 07:03PM	BIIB, DNLI Stocks Edge Lower After Hours: Parkinsons Drug Misses Key Goals In Trial (Stocktwits)
06:00PM	Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease (GlobeNewswire)
May-19-26 09:33AM	Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout (Proactive)
May-15-26 09:45AM	Cisco upgraded, Doximity downgraded: Wall Street's top analyst calls (The Fly)
07:44AM	Biogen completes $5.3B Apellis Pharmaceuticals acquisition (Quartz)
May-14-26 07:19PM	Biogen Shares Jump 10% After Advancing Alzheimer's Tau Drug (GuruFocus.com) -6.43%
04:30PM	Biogen Inc. stock underperforms Thursday when compared to competitors (MarketWatch)
01:03PM	Biogen Is Celebrating A First In Alzheimer's Disease. But Investors Are Leery. (Investor's Business Daily)
10:08AM	Biogen Shares Surge After Positive Mid-Stage Alzheimers Trial Results (InvestorsHub)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Godbout Sean	Chief Accounting Officer	Oct 02 '26	Option Exercise	0.00	27	0	1,467	Oct 05 05:00 PM
Minor Lloyd	Director	Aug 03 '26	Sale	203.34	593	120,581	3,282	Aug 05 04:03 PM
Minor Lloyd	Director	Aug 04 '26	Sale	200.96	593	119,169	2,689	Aug 05 04:03 PM
Minor Lloyd	Director	Aug 04 '26	Proposed Sale	200.96	593	119,169		Aug 04 11:22 AM
Minor Lloyd	Director	Aug 03 '26	Proposed Sale	203.34	593	120,581		Aug 03 01:02 PM
Pangalos Menelas N	Director	Jun 09 '26	Option Exercise	0.00	2,370	0	2,370	Jun 11 05:21 PM
Keeney Adam	Head of Corporate Development	May 01 '26	Option Exercise	0.00	939	0	6,820	May 05 04:11 PM
Godbout Sean	Chief Accounting Officer	Apr 01 '26	Option Exercise	0.00	181	0	1,396	Apr 03 04:05 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 12 '26	Buy	195.03	3	585	19,611	Feb 17 08:16 PM
Viehbacher Christopher	President and CEO	Feb 06 '26	Option Exercise	0.00	24,461	0	36,548	Feb 10 05:06 PM
Singhal Priya	Head of Development	Feb 06 '26	Option Exercise	0.00	6,900	0	12,115	Feb 10 05:05 PM
Singhal Priya	Head of Development	Feb 09 '26	Sale	199.83	2,660	531,548	8,043	Feb 10 05:05 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 06 '26	Option Exercise	0.00	8,725	0	21,016	Feb 10 05:03 PM
Kramer Robin	Chief Financial Officer	Feb 06 '26	Option Exercise	0.00	5,003	0	12,535	Feb 10 05:02 PM
Keeney Adam	Head of Corporate Development	Feb 06 '26	Option Exercise	0.00	5,080	0	6,875	Feb 10 05:01 PM
Izzar Rachid	Head of Global Product Strat.	Feb 06 '26	Option Exercise	0.00	6,889	0	11,786	Feb 10 05:00 PM
Grogan Jane	Head of Research	Feb 06 '26	Option Exercise	0.00	3,258	0	4,642	Feb 10 04:59 PM
Gregory Ginger	EVP, Human Resources	Feb 06 '26	Option Exercise	0.00	7,183	0	23,491	Feb 10 04:58 PM
Godbout Sean	Chief Accounting Officer	Feb 06 '26	Option Exercise	0.00	1,079	0	1,395	Feb 10 04:56 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 06 '26	Option Exercise	0.00	9,046	0	43,321	Feb 10 04:55 PM
Singhal Priya	Officer	Feb 09 '26	Proposed Sale	199.83	2,660	531,548		Feb 09 10:14 AM
Singhal Priya	Head of Development	Jan 30 '26	Option Exercise	0.00	1,829	0	7,601	Feb 03 05:17 PM
Singhal Priya	Head of Development	Feb 02 '26	Sale	179.30	748	134,116	6,271	Feb 03 05:17 PM
Singhal Priya	Officer	Feb 02 '26	Proposed Sale	179.30	748	134,116		Feb 02 11:10 AM
Viehbacher Christopher	President and CEO	Dec 01 '25	Option Exercise	0.00	7,040	0	19,847	Dec 03 04:42 PM
Grogan Jane	Head of Research	Oct 31 '25	Option Exercise	0.00	695	0	2,128	Nov 04 04:12 PM

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

PresidentMr. Christopher A. Viehbacher

Executive VP & CFOMs. Robin C. Kramer

Executive VP and Head of Pharmaceutical Operations & TechnologyMs. Nicole Murphy

M.P.H.Dr. Priya Singhal M.D.

VPMr. Sean Godbout

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Biogen Inc

Upgrade your Finviz experience